{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:11:52Z","timestamp":1791270712149,"version":"4.1.0"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2015,3,18]],"date-time":"2015-03-18T00:00:00Z","timestamp":1426636800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0119160","type":"journal-article","created":{"date-parts":[[2015,3,18]],"date-time":"2015-03-18T20:24:16Z","timestamp":1426710256000},"page":"e0119160","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":21,"title":["The Prognostic Value of Plasma Galectin-3 in Chronic Heart Failure Patients Is Maintained when Treated with Mineralocorticoid Receptor Antagonists"],"prefix":"10.1371","volume":"10","author":[{"given":"Fran\u00e7ois","family":"Koukoui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Desmoulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Galinier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Barutaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Caub\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Francesca","family":"Evaristi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurbuz","family":"Murat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"De Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Smih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Rouet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,3,18]]},"reference":[{"issue":"33","key":"ref1","first-page":"20807","article-title":"Galectins. Structure and function of a large family of animal lectins. J Biol Chem","volume":"269","author":"SH Barondes","year":"1994","journal-title":"Galectins. Structure and function of a large family of animal lectins. J Biol Chem"},{"issue":"2\u20133","key":"ref2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0304-4165(02)00310-0","article-title":"Galectinomics: finding themes in complexity","volume":"1572","author":"DN Cooper","year":"2002","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"ref3","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.bbagen.2005.12.020","article-title":"Galectin-3: an open-ended story","volume":"1760","author":"J Dumic","year":"2006","journal-title":"Biochim Biophys Acta"},{"issue":"19","key":"ref4","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1161\/01.CIR.0000147181.65298.4D","article-title":"Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction","volume":"110","author":"UC Sharma","year":"2004","journal-title":"Circulation"},{"issue":"9","key":"ref5","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/eurjhf\/hfp097","article-title":"Galectin-3: a novel mediator of heart failure development and progression","volume":"11","author":"RA de Boer","year":"2009","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"ref6","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jacc.2006.03.061","article-title":"Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure","volume":"48","author":"RR van Kimmenade","year":"2006","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3109\/07853890.2010.538080","article-title":"Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction","volume":"43","author":"RA de Boer","year":"2011","journal-title":"Ann Med"},{"issue":"5","key":"ref8","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00392-010-0125-y","article-title":"Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study","volume":"99","author":"DJ Lok","year":"2010","journal-title":"Clin Res Cardiol"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2796.2011.02476.x","article-title":"The fibrosis marker galectin-3 and outcome in the general population","volume":"272","author":"RA de Boer","year":"2012","journal-title":"J Intern Med"},{"issue":"14","key":"ref10","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2012.04.053","article-title":"Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community","volume":"60","author":"JE Ho","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"ref11","first-page":"e147","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"CW Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"ref12","doi-asserted-by":"crossref","first-page":"e000760","DOI":"10.1161\/JAHA.112.000760","article-title":"Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure","volume":"1","author":"DM Gopal","year":"2012","journal-title":"J Am Heart Assoc"},{"issue":"1\u20132","key":"ref13","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.cca.2009.09.001","article-title":"The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients","volume":"409","author":"YH Lin","year":"2009","journal-title":"Clin Chim Acta"},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1161\/CIRCHEARTFAILURE.112.971168","article-title":"Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis","volume":"6","author":"L Yu","year":"2013","journal-title":"Circ Heart Fail"},{"issue":"2","key":"ref15","doi-asserted-by":"crossref","first-page":"288","DOI":"10.2353\/ajpath.2008.070726","article-title":"Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis","volume":"172","author":"NC Henderson","year":"2008","journal-title":"Am J Pathol"},{"issue":"13","key":"ref16","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1073\/pnas.0511167103","article-title":"Galectin-3 regulates myofibroblast activation and hepatic fibrosis","volume":"103","author":"NC Henderson","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"ref17","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1164\/rccm.201106-0965OC","article-title":"Regulation of transforming growth factor-beta1-driven lung fibrosis by galectin-3","volume":"185","author":"AC Mackinnon","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"ref18","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1210\/jc.2003-030373","article-title":"Aldosterone: direct effects on and production by the heart","volume":"88","author":"PC White","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"ref19","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1161\/ATVBAHA.112.300569","article-title":"Galectin-3 mediates aldosterone-induced vascular fibrosis","volume":"33","author":"L Calvier","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"ref20","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/eurjhf\/hfs105","article-title":"ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC","volume":"14","author":"JJ McMurray","year":"2012","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"ref21","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s000590050024","article-title":"Aldosterone and myocardial fibrosis in heart failure","volume":"25","author":"CG Brilla","year":"2000","journal-title":"Herz"},{"issue":"22","key":"ref22","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1161\/01.CIR.102.22.2700","article-title":"Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES)","volume":"102","author":"F Zannad","year":"2000","journal-title":"Rales Investigators. Circulation"},{"issue":"1","key":"ref23","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cardfail.2013.11.011","article-title":"Relationship between galectin-3 levels and mineralocorticoid receptor antagonist use in heart failure: analysis from HF-ACTION","volume":"20","author":"M Fiuzat","year":"2014","journal-title":"J Card Fail"},{"issue":"6","key":"ref24","doi-asserted-by":"crossref","first-page":"e20414","DOI":"10.1371\/journal.pone.0020414","article-title":"Blood signature of pre-heart failure: a microarrays study","volume":"6","author":"F Smih","year":"2011","journal-title":"PLoS One"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/pan\/mpl013","article-title":"Matching as Nonparametric Preprocessing for Reducing Model Dependence in Parametric Causal Inference","volume":"15","author":"D Ho","year":"2007","journal-title":"Political Analysis"},{"issue":"2","key":"ref26","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","author":"PC Austin","year":"2011","journal-title":"Pharm Stat"},{"issue":"4","key":"ref27","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3909\/ricm0624","article-title":"Galectin-3: a novel blood test for the evaluation and management of patients with heart failure","volume":"12","author":"PA McCullough","year":"2011","journal-title":"Rev Cardiovasc Med"},{"issue":"3","key":"ref28","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijcard.2013.08.081","article-title":"Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction","volume":"169","author":"FJ Carrasco-Sanchez","year":"2013","journal-title":"Int J Cardiol"},{"issue":"2","key":"ref29","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1161\/CIRCHEARTFAILURE.112.000129","article-title":"Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH","volume":"6","author":"AR van der Velde","year":"2013","journal-title":"Circ Heart Fail"},{"issue":"10","key":"ref30","first-page":"1499","article-title":"Structural myocardial alterations in diabetes and hypertension: the role of galectin-3","volume":"52","author":"JP Seferovic","year":"2014","journal-title":"Clin Chem Lab Med"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"983098","DOI":"10.1155\/2014\/983098","article-title":"Usefulness of combining galectin-3 and BIVA assessments in predicting short- and long-term events in patients admitted for acute heart failure","volume":"2014","author":"B De Berardinis","year":"2014","journal-title":"Biomed Res Int"},{"issue":"2","key":"ref32","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/HPC.0000000000000012","article-title":"Emergency department use of galectin-3","volume":"13","author":"WF Peacock","year":"2014","journal-title":"Crit Pathw Cardiol"},{"issue":"18","key":"ref33","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1093\/eurheartj\/ehs077","article-title":"Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)","volume":"33","author":"L Gullestad","year":"2012","journal-title":"Eur Heart J"},{"issue":"10","key":"ref34","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"B Pitt","year":"1999","journal-title":"N Engl J Med"},{"issue":"36","key":"ref35","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1093\/eurheartj\/eht247","article-title":"The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial","volume":"34","author":"TJ Collier","year":"2013","journal-title":"Eur Heart J"},{"issue":"19","key":"ref36","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.jacc.2011.04.049","article-title":"Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy","volume":"58","author":"P Rossignol","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"ref37","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ijcard.2011.12.080","article-title":"Effects of mineralocorticoid receptor antagonist spironolactone on cardiac sympathetic nerve activity and prognosis in patients with chronic heart failure","volume":"167","author":"S Kasama","year":"2013","journal-title":"Int J Cardiol"},{"issue":"20","key":"ref38","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1001\/jama.2012.14795","article-title":"Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction","volume":"308","author":"AF Hernandez","year":"2012","journal-title":"JAMA"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0119160","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T12:00:33Z","timestamp":1651579233000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0119160"}},"subtitle":[],"editor":[{"given":"Harald","family":"Mischak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,3,18]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,3,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0119160","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,18]]}}}